OBJECTIVE: We hypothesized that (1) neointima formation in a rat carotid balloon injury model could be reduced in vivo following targeted ultrasound delivery of rapamycin microbubbles (RMBs), and (2) the addition of dual-mode ultrasound decreases the total amount of drug needed to reduce neointima formation. METHODS AND RESULTS: Balloon injury was performed in rat carotids to induce neointima formation. High or low doses of RMBs were injected intravenously and ruptured at the site of injury with ultrasound. Compared with nontreated injured arteries, neointima formation was reduced by 0% and 35.9% with 10(8) RMBs and by 28.7% and 34.9% in arteries treated with 10(9) RMBs with and without ultrasound, respectively. CONCLUSIONS: Without ultrasound, 10-fold higher concentrations of RMBs were needed to reduce neointima formation by at least 28%, whereas 10(8) RMBs combined with ultrasound were sufficient to achieve the same therapeutic effect, demonstrating that this technology may have promise for localized potent drug therapy.
OBJECTIVE: We hypothesized that (1) neointima formation in a rat carotid balloon injury model could be reduced in vivo following targeted ultrasound delivery of rapamycin microbubbles (RMBs), and (2) the addition of dual-mode ultrasound decreases the total amount of drug needed to reduce neointima formation. METHODS AND RESULTS:Balloon injury was performed in rat carotids to induce neointima formation. High or low doses of RMBs were injected intravenously and ruptured at the site of injury with ultrasound. Compared with nontreated injured arteries, neointima formation was reduced by 0% and 35.9% with 10(8) RMBs and by 28.7% and 34.9% in arteries treated with 10(9) RMBs with and without ultrasound, respectively. CONCLUSIONS: Without ultrasound, 10-fold higher concentrations of RMBs were needed to reduce neointima formation by at least 28%, whereas 10(8) RMBs combined with ultrasound were sufficient to achieve the same therapeutic effect, demonstrating that this technology may have promise for localized potent drug therapy.
Authors: Linsey C Phillips; Alexander L Klibanov; Douglas K Bowles; Michael Ragosta; John A Hossack; Brian R Wamhoff Journal: J Vasc Res Date: 2009-11-18 Impact factor: 1.934
Authors: Kurt A Zimmerman; Dongqi Xing; Manuel A Pallero; Ailing Lu; Masahito Ikawa; Leland Black; Kenneth L Hoyt; Janusz H Kabarowski; Marek Michalak; Joanne E Murphy-Ullrich Journal: J Vasc Res Date: 2016-02-25 Impact factor: 1.934
Authors: Joseph P Kilroy; Abhay V Patil; Joshua J Rychak; John A Hossack Journal: IEEE Trans Ultrason Ferroelectr Freq Control Date: 2014-03 Impact factor: 2.725
Authors: Joseph P Kilroy; Ali H Dhanaliwala; Alexander L Klibanov; Douglas K Bowles; Brian R Wamhoff; John A Hossack Journal: Ann Biomed Eng Date: 2015-04-17 Impact factor: 3.934
Authors: Joseph P Kilroy; Alexander L Klibanov; Brian R Wamhoff; Douglas K Bowles; John A Hossack Journal: Ultrasound Med Biol Date: 2014-08-15 Impact factor: 2.998
Authors: Ramasamy Paulmurugan; Bryan Oronsky; Chad F Brouse; Tony Reid; Susan Knox; Jan Scicinski Journal: Theranostics Date: 2013-05-25 Impact factor: 11.556